Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Janssen logo

Janssen

Status

Conditions

Relapsed or Refractory Multiple Myeloma

Treatments

Drug: Talquetamab

Study type

Expanded Access

Funder types

Industry

Identifiers

NCT05503550
CR109169
64407564MMY4002 (Other Identifier)

Details and patient eligibility

About

The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.

Sex

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems